Last reviewed · How we verify
Mefoxin In Sodium Chloride 0.9% In Plastic Container (CEFOXITIN)
Mefoxin In Sodium Chloride 0.9% In Plastic Container (Cefoxitin) is a cephalosporin antibacterial medication. Originally developed by Upjohn, it is now owned by Pharmobedient. Cefoxitin is a small molecule modality that was FDA approved in 1978 for various bacterial infections, including abdominal abscess, bacterial pneumonia, and urinary infections. It is available as a generic medication, with 8 generic manufacturers. Cefoxitin is off-patent, with no active Orange Book patents.
At a glance
| Generic name | CEFOXITIN |
|---|---|
| Sponsor | Pharmobedient |
| Drug class | Cephalosporin Antibacterial |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Lower respiratory tract infections
- Urinary tract infections
- Intra-abdominal infections
- Gynecological infections
- Septicemia
- Bone and joint infections
- Skin and skin structure infections
- Prophylaxis of infection in surgery
Common side effects
- Thrombophlebitis
- Rash
- Urticaria
- Flushing
- Pruritus
- Eosinophilia
- Fever
- Dyspnea
- Hypotension
- Diarrhea
- Nausea
- Vomiting
Drug interactions
- aminoglycoside antibiotics
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Precision Antibiotic Dosing for Appendectomy (PHASE1)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? (PHASE3)
- The Expected Advantage of Administering Prophylactic Antibiotics Using Target- Concentration Controlled Infusion (NA)
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2,PHASE3)
- Duration of Perioperative Antibiotics in Pancreatoduodenectomy (NA)
- Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mefoxin In Sodium Chloride 0.9% In Plastic Container CI brief — competitive landscape report
- Mefoxin In Sodium Chloride 0.9% In Plastic Container updates RSS · CI watch RSS